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Salicylate reduces cisplatin nephrotoxicity by inhibition
of tumor necrosis factor-a
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Salicylate reduces cisplatin nephrotoxicity by inhibition of tu-
mor necrosis factor-a .
Background. Salicylate was recently shown to provide
protection against cisplatin nephrotoxicity in rats. We have
demonstrated that enhanced tumor necrosis factor-a (TNF-a)
production mediates, in part, cisplatin nephrotoxicity. The pur-
pose of this study was to determine if the protective effects of
salicylate were mediated through inhibition of TNF-a in vivo
and to explore the mechanism of inhibition in vitro.
Methods. The effects of treatment with cisplatin alone and in
combination with sodium salicylate in mice on renal function,
histology, and gene expression were determined. The effects
of cisplatin and salicylate on TNF-a expression, nuclear factor
kappa B (NF-jB) activity, and apoptosis were determined in
vitro using cultured murine proximal tubule cells.
Results. Salicylate significantly reduced both the functional
and histologic evidence of cisplatin renal injury. Cisplatin in-
creased the renal expression of TNF-a, monocyte chemoat-
tractant protein-1 (MCP-1), intercellular adhesion molecule
(ICAM)-1, heme oxygenase-1, TNF receptor 1 (TNFR1), and
TNF receptor 2 (TNFR2). Treatment with sodium salicylate
blunted the increase in TNF-a mRNA and also reduced serum
TNF-a protein levels. Salicylate had little protective effect
when administered with cisplatin to TNF-a–deficient mice. Cis-
platin increased the degradation of I kappa B (IjB) in a time-
dependent manner and also increased nuclear NF-jB binding
activity. Salicylate inhibited IjB degradation and NF-jB bind-
ing activity in the presence of cisplatin. In addition, salicylate
inhibited the cisplatin induced TNF-a mRNA increase in mouse
proximal tubule epithelial (TKPT) cells.
Conclusion. These results indicate that salicylate acts via inhi-
bition of TNF-a production to reduce cisplatin nephrotoxicity.
The inhibition of TNF-a production may be mediated via sta-
bilization of IjB.
Cisplatin is a highly effective antitumor agent used to
treat a wide variety of malignancies [1]. The key limi-
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tation of this chemotherapeutic agent is nephrotoxicity.
Approximately 25%–35% of patients experience a signif-
icant decline in renal function after a single dose of cis-
platin [2]. Recent evidence indicates that inflammatory
mechanisms play an important role in the pathogen-
esis of cisplatin-induced renal injury. Tumor necrosis
factor-a (TNF-a), in particular, is increased in cisplatin
injury [3–5] and coordinates the activation of a large net-
work of chemokines and cytokines in the kidney follow-
ing cisplatin injection [5]. Moreover, inhibition of either
TNF-a production or its activity ameliorates cisplatin-
induced renal dysfunction and reduces cisplatin-induced
structural damage [5, 6]. These observations indicate that
TNF-a plays an important role in cisplatin injury. TNF-a
may also play a role in ischemic and myoglobinuric acute
renal failure [7, 8].
Salicylates are widely used in the treatment of inflam-
matory conditions such as rheumatic fever and rheuma-
toid arthritis. The anti-inflammatory actions of salicylates,
and other nonsteroidal anti-inflammatory agents, have
generally been attributed to their inhibition of cyclooxy-
genase activity and prostaglandin synthesis. However,
high doses of salicylates also inhibit the activity of IjB
kinase b (IKK), thereby reducing nuclear factor kappa
B (NF-jB) transcriptional activity [9, 10]. Salicylate was
recently shown to reduce cisplatin nephrotoxicity [11], al-
though no mechanism was determined. Because TNF-a
is involved in the pathogenesis of cisplatin nephrotoxicity
[5, 6], and because TNF-a production is under transcrip-
tional control by NF-jB [12], the current studies were
performed to determine if salicylates reduce cisplatin-
induced renal dysfunction by inhibiting the production
of TNF-a.
We found that salicylates significantly reduced cisplatin
nephrotoxicity and also reduced TNF-a production in
response to cisplatin. Salicylates had minimal protective
actions in TNF-a–deficient mice. In vitro studies demon-
strated that cisplatin increased TNF-a production by cul-
tured murine proximal tubule cells and increased the
degradation of IjB and NF-jB binding activity. These ac-
tions were inhibited by salicylate. These results indicate
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that salicylates protect from cisplatin nephrotoxicity by
reducing TNF-a production and/or action in vivo. This
effect may be mediated by inhibition of IjB degradation.
METHODS
Animals and drug administration
Experiments were performed on 10- to 12-week-old
male C57BL/6, B6129SF2/J, or TNF-a–deficient mice
(B6129-Tnftm1Gkl) weighing approximately 30 g. Mice
were obtained from the Jackson Laboratory (Bar Harbor,
ME, USA) and were maintained on a standard diet and
water was freely available. Cisplatin (Sigma-Aldrich, St.
Louis, MO, USA) was dissolved in saline at a concentra-
tion of 1 mg/mL. Mice were given a single intraperitoneal
injection of either vehicle (saline) or cisplatin (20 mg/
kg BW). This dose of cisplatin produces severe renal fail-
ure in mice [5, 13]. Some groups also received subcu-
taneous injection of sodium salicylate (100 mg/kg BW)
either alone or with cisplatin. The salicylate was adminis-
tered twice a day, beginning 24 hours prior to the cisplatin
injection and was continued for 6 doses. Animals were
sacrificed 72 hours after cisplatin injection and blood and
kidney tissues were collected. Tissues were processed for
histology and RNA isolation.
Renal function
Renal function was assessed by measurements of blood
urea nitrogen and serum creatinine using commercially
available kits (Sigma).
Quantitation of mRNA by real-time PCR
Total RNA was isolated from kidney using Tri-
zol reagent. Real-time reverse transcription coupled
polymerase chain reaction (RT-PCR) was performed
in an Applied Biosystems 7700 Sequence Detection
System (Foster City, CA, USA). Total RNA (5 lg)
was reverse transcribed in a reaction volume of 20 lL
using Superscript II (Invitrogen, Carlsbad, CA, USA)
reverse transcriptase and random primers. The product
was diluted to a volume of 500 lL and either 2lL
(actin) or 10 lL (all others) aliquots were used as
templates for amplification using the SYBR Green PCR
amplification reagent (Applied Biosystems) and gene
specific primers. The primer sets used were: actin (for-
ward:CATGGATGACGATATCGCT; reverse:CATGA
GGTAGTCTGTCAGGT), TNF-a (forward:GCATGA
TCCGCGACGTGGAA; reverse:AGATCCATGCCG
TTGGCCAG), TNFR1 (forward: CCGGGCCACCTG
GTCCG; reverse: CAAGTAGGTTCCTTTGTG),
TNFR2 (forward: GTCGCGCTGGTCTTCGAACTG;
reverse: GGTATACATGCTTGCCTCACAGTC),
ICAM-1 (forward:AGATCACATTCACGGTGCTG;
reverse:CTTCAGAGGCAGGAAACAGG), Heme
oxygenase-1 (forward:AGCATGCCCCAGGATTTG;
reverse: AGCTCAATGTTGAGCAGGA), and MCP-
1 (forward: ATGCAGGTCCCTGTCATG; reverse:
GCTTGAGGTGGTTGTGGA). The amount of result-
ing DNA was normalized to the actin signal amplified in
a separate reaction.
TNF-a quantitation by ELISA
Levels of TNF-a in serum were determined using an
enzyme-linked immunosorbent assay (ELISA) (Quan-
tikine Mouse TNF-a kit; R&D Systems, Inc., Min-
neapolis, MN, USA) according to the manufacturer’s
instructions.
Histology and histochemistry
Kidney tissue was fixed in buffered 10% formalin for
12 hours and then embedded in paraffin wax. Five-micron
thick sections were stained with PAS or naphthol AS-D
choroacetate esterase (Sigma, kit # 91C). The esterase
stain identifies infiltrating neutrophils and monocytes.
Thirty 40× fields of esterase stained sections were exam-
ined for quantitation of leukocytes. Tubular injury was as-
sessed in PAS-stained sections using a semi-quantitative
scale [3, 14, 15] in which the percentage of cortical tubules
showing epithelial necrosis was assigned a score: 0 = nor-
mal; 1 =<10%; 2 = 10%–25%; 3 = 26%–75%; 4 =>75%.
Apoptosis was scored by counting the number of apop-
totic cells, as defined by chromatin condensation or nu-
clear fragmentation (apoptotic bodies), on PAS-stained
sections. The individual scoring of the slides was blinded
to the treatment and strain of the animal.
Renal platinum content
Kidneys were removed 48 hours after injection and
digested in a mixture of Ultrex trace metal grade ni-
tric acid and hydrochloric acid (J.T. Baker, Phillipsburg,
NJ, USA) for one hour at 100◦C. The digested samples
were diluted with high-purity water and subjected to in-
ductively coupled plasma/mass spectroscopy (ICP/MS)
(Elan 6000; Perkin-Elmer, Boston, MA, USA) to deter-
mine the platinum content. ICP/MS has been shown to be
superior to either atomic absorption spectrometry or in-
ductively coupled plasma atomic emission spectrometry
for the measurement of tissue platinum [16].
Cell culture and Western blot analysis
Mouse proximal tubule epithelial cells (TKPT cells,
kindly provided by E. Bello-Reuss) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM)-F12
medium containing antibiotics and 7.5% fetal bovine
serum until confluent. Cells were treated with 100 lmol/L
cisplatin with or without 20 lmol/L sodium salicylate
for varying times. At the end of the treatment, the cells
were harvested and used for RNA isolation and pro-
tein extraction. RNA was isolated using Trizol reagent.
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Proteins were extracted by solubilizing the cells in ra-
dioimmunoprecipitation (RIPA) buffer containing a pro-
tease and phosphatase inhibitor cocktail (Sigma). Protein
concentrations were quantitated (BCA protein assay
reagent; Pierce, Rockford, IL, USA) and 100 lg sam-
ples of protein were separated by 10% sodium dode-
cyl sulfate (SDS) polyacrylamide gel electrophoresis and
then transferred onto a polyvinylidene fluoride (PVDF)
membrane. Western blot analysis was performed with an
anti-IjB antibody (1:1000 dilution; Cell Signaling, Bev-
erly, MA, USA). Proteins were detected using enhanced
chemiluminescence detection reagents (Amersham Phar-
macia Biotech, Piscataway, NJ, USA).
Preparation of nuclear extract
Cells treated with various agents were scraped and
washed with ice-cold phosphate-buffered saline (PBS)
and then resuspended in 200 lL of ice-cold lysis buffer
(10 mmol/L HEPES pH 7.9, 10 mmol/L KCl, 0.4% NP-
40, 1.5 mmol/L MgCl2, 1 mmol/L dithiothreitol (DTT),
0.1 mmol/L EDTA, and 1× protease cocktail inhibitor
(Sigma). After 10 minute on ice, the lysate was cen-
trifuged at 12, 000g for 1 minute at 4◦C. The nuclear
pellet was washed once with lysis buffer and then ex-
tracted with a buffer containing 20 mmol/L HEPES (pH
7.9), 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L
EDTA, 1 mmol/L DTT, and 1× protease inhibitor cock-
tail (Sigma) and centrifuged at 12, 000g for 10 minutes at
4◦C. The supernatant was stored at −80◦C until use.
Electromobility shift assay
An NF-jB consensus oligonucleotide (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was 5′ end-labeled
with [c -32P] ATP using T4 polynucleotide kinase. Nuclear
protein (15 lg) was incubated with the labeled oligonu-
cleotide (2.0 × 105 cpm) in binding buffer (10 mmol/L
HEPES pH 7.5, 0.1 mol/L EDTA, 0.1 mmol/L DTT, 0.1
mmol/L MgCl2, 50 mmol/L NaCl, 1 mmol/L CaCl2, and
2% glycerol) for 20 minutes at room temperature in a fi-
nal volume of 20 lL. Subsequently, free oligonucleotide
and oligonucleotide-protein complexes were resolved by
electrophoresis on a 4–12% TB-polyacrylamide gel (In-
vitrogen) and detected by autoradiography. The speci-
ficity of the NF-jB binding was determined by adding
20-fold excess unlabeled oligonucleotide or mutant
oligonucleotide in the binding reaction.
DNA fragmentation
Apoptotic DNA fragments were isolated using the
method of Herrmann et al [17]. Cells were washed with
PBS, scraped from the dish, and centrifuged at 1000g
for 3 minutes. The cell pellets were lysed (1% NP-40 in
20 mmol/L EDTA, 50 mmol/L Tris-HCl, pH 7.5) and
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Fig. 1. Effect of salicylate and cisplatin on renal function. Mice were
injected with 20 mg/kg cisplatin and/or 100 mg/kg sodium salicylate
as described in Methods. Blood urea nitrogen (solid bars) and plasma
creatinine (hatched bars) were measured 72 hours after injection. Cis-
platin caused severe renal dysfunction that was partially prevented by
salicylate. +P < 0.005 vs. saline; ∗P < 0.0005 vs. cisplatin. N = 4 to 5.
centrifuged to remove nuclei and unlysed cells. SDS and
Rnase A were added to the supernatant and incubated
at 56◦C for 1 hour, followed by digestion with proteinase
K for 2 hours at 37◦C. The DNA fragments were pre-
cipitated with ammonium acetate and ethanol and then
separated by electrophoresis in 1.8% agarose gels. The
gels were stained with ethidium bromide and visualized
under ultraviolet light.
Statistical methods
All assays were performed in duplicate. The data are
reported as mean ± SEM. Statistical significance was as-
sessed by unpaired, two-tailed Student t test for single
comparison, or analysis of variance (ANOVA) for multi-
ple comparisons.
RESULTS
Salicylate provides functional and structural protection
from cisplatin nephrotoxicity
To examine the effect of salicylate on cisplatin-induced
kidney dysfunction, we administered cisplatin alone or in
combination with salicylate to mice. As shown in Figure 1,
cisplatin injection produced severe renal failure. In con-
trast, administration of salicylate together with cisplatin
significantly reduced both the BUN (210 ± 14 vs. 98 ±
25 mg/dL, P < 0.005) and creatinine (3.6 ± 0.4 vs. 1.0 ±
0.3 mg/dL, P = 0.0005) levels compared with cisplatin
alone. Salicylate alone did not affect either urea or cre-
atinine values. Similar reductions in urea and creatinine
were reported by Li et al [11] in the rat. The improve-
ment in renal function was accompanied by less severe
histologic damage. As shown Figure 2, cisplatin treatment
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Fig. 2. Effect of salicylate and cisplatin on re-
nal histology. Mice were treated with saline
(A), salicylate (B), cisplatin (C), or cisplatin
and salicylate (D). Kidneys were harvested
72 hours after injection. The cisplatin-treated
kidneys (C) demonstrated marked injury with
loss of brush border, necrosis, and loss of
epithelial cells and cast formation. These
changes were reduced in salicylate-treated
mice (D). Salicylate treatment alone (B) had
no effect on renal histology.
resulted in severe tubular injury reflected by cast for-
mation, loss of brush border membranes, sloughing of
tubular epithelial cells, and dilation of tubules. These
changes were markedly reduced in kidneys from animals
injected with cisplatin and salicylate. Figure 3 presents a
semi-quantitative measure of tubular necrosis and apop-
tosis. Consistent with previous reports [13, 18], cisplatin
produced a large increase in both necrosis and apopto-
sis. Both forms of cell death were significantly reduced
by salicylate. We used morphologic criteria rather than
biochemical detection methods [e.g., terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end-labeling
(TUNEL) or annexin staining) to detect apoptosis. Mor-
phologic criteria remain the gold standard for the identi-
fication of apoptosis. In ischemia/reperfusion injury and
cisplatin renal injury, there is a good correlation between
morphologically defined apoptosis and TUNEL staining
[19, 20]. The improvements in renal function and histol-
ogy were not caused by an inhibition of platinum uptake
in the kidney by salicylate. In fact, the platinum content of
kidneys of mice treated with cisplatin plus salicylate was
actually greater than in mice treated with cisplatin alone
(8013 ± 464 vs. 5110 ± 352 lg Pt/kg tissue, P < 0.001,
N = 3).
Salicylate reduces leukocyte infiltration
in cisplatin nephrotoxicity
Cisplatin nephrotoxicity is characterized by the infil-
tration of inflammatory cells into the kidney [4, 5]. We
determined the effect of salicylate on this process. As
shown in Figure 4, cisplatin injection produced a large in-
crease in leukocytes within the kidney cortex and this
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Fig. 3. Effect of salicylate and cisplatin on tubular necrosis and apop-
tosis. Tubular necrosis (solid bars) and apoptosis (hatched bars) were
scored in kidneys from mice treated with saline, salicylate, cisplatin, or
cisplatin and salicylate. +P < 0.001 vs. saline; ∗P < 0.001 vs. cisplatin.
N = 3 to 5.
increase was significantly reduced in the presence of
salicylate.
Salicylate inhibits the up-regulation of cytokine and ad-
hesion molecule expression in cisplatin nephrotoxicity
We have previously shown that cisplatin results in
the up-regulation of a number of pro-inflammatory
chemokines and cytokines in the kidney [5]. Experi-
ments were performed to determine if the salutary ac-
tions of salicylate (Figs. 1–4) involved suppression of this
cytokine response. Kidneys were harvested at 72 hours
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Fig. 4. Effect of salicylate and cisplatin on renal leukocyte infiltration.
Kidneys were harvested 72 hours after the indicated treatment and
stained with naphthol AS-D choroacetate esterase. Leukocytes in 30
×40 fields were counted for each animal. +P < 0.05 vs. cisplatin. N = 3
to 7.
after treatment with cisplatin in the presence or ab-
sence of salicylate. Cytokine gene expression was deter-
mined by real-time RT-PCR (Fig. 5). TNF-a, monocyte
chemoattractant protein-1 (MCP-1), as well as TNF re-
ceptor 1 (TNFR1) and TNF receptor 2 (TNFR2) were
up-regulated after cisplatin injection. TNFR2 was up-
regulated to a greater extent than TNFR1. In addition,
intercellular adhesion molecule-1 (ICAM-1) and an ox-
idative stress marker, heme oxygenase–1 (HO-1), were
also up-regulated. Treatment with salicylate significantly
inhibited the up-regulation of TNF-a. TNFR2 expression
was reduced slightly but this did not achieve statistical
significance. The expression of TNFR1, MCP-1, ICAM-
1, and HO-1 were not affected by salicylate. In addition,
serum TNF-a protein levels (Fig. 6) were also significantly
reduced in cisplatin- and salicylate-treated animals when
compared to cisplatin-treated animals (81 ± 23 vs. 18 ±
5 pg/mL, P < 0.05).
Salicylate inhibits cisplatin toxicity via suppression
of TNF-a production
To determine if the beneficial effects of salicylate on re-
nal function and structure (Figs. 1–4) were due to inhibi-
tion of TNF-a production (Figs. 5 and 6), we examined the
effects of salicylate in TNF-a deficient mice. Wild-type
B6129S mice or TNF-a–deficient mice received 20 mg/
kg cisplatin in the presence or absence of sodium sali-
cylate. As shown in Figure 7, wild-type mice developed
severe renal failure, and, consistent with the results in
Figure 1, this was significantly reduced by salicylate. As
we reported earlier [5], TNF-a–deficient mice developed
less renal dysfunction when compared to the wild-type
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Fig. 5. Effect of cisplatin and salicylate on renal gene expression. Kid-
neys were harvested 72 hours after treatment with saline (open bars),
cisplatin (solid bars), or cisplatin and salicylate (hatched bars). Ex-
pression of the indicated genes was determined by real-time reverse
transcription-polymerase chain reaction (RT-PCR). N = 4 to 8 in each
group. ∗P < 0.05 vs. saline; +P < 0.05 vs. cisplatin.
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Fig. 6. Effect of cisplatin and salicylate on serum tumor necrosis fac-
tor a (TNFa ) levels. Serum TNFa concentrations were determined 72
hours after treatment with the indicated agents. +P < 0.05 vs. cisplatin.
N = 5 in each group.
mice. Of note, salicylate had no additional benefit in the
absence of endogenous TNF-a.
Salicylate inhibits cisplatin-induced IjB degradation,
NF-jB binding activity, and TNF-a expression
in proximal tubule cells
As noted earlier, salicylates can inhibit IKK activity,
thereby reducing IjB degradation and subsequent NF-
jB transcriptional activity [9, 10]. To determine if such
a mechanism could account for the observed reduction
in renal TNF-a expression (Fig. 5), cultured TKPT cells
were treated with 100 lmol/L cisplatin or cisplatin plus
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Fig. 7. Tumor necrosis factor a (TNFa )-dependence of salicylate ac-
tions in cisplatin nephrotoxicity. B6129SF/J- or TNFa–deficient mice
were treated with either cisplatin or cisplatin and salicylate. Blood urea
nitrogen (solid bars) or serum creatinine (hatched bars) was measured
72 hours after injection. +P < 0.05 vs. cisplatin. ++P < 0.01 vs. cisplatin
B6129SF/J. N = 5 in each group.
20 mmol/L sodium salicylate. As shown in Figure 8,
cisplatin increased the degradation of IjB in a time-
dependent manner. However, in the presence of salicy-
late this degradation of IjB was inhibited. Degradation
of IjB allows the nuclear localization of NF-jB and sub-
sequent transcriptional activation of target genes [12],
including TNF-a [21]. Gel-shift assays were performed
to evaluate the effects of cisplatin and salicylate on NF-
jB binding activity. As shown in Figure 9, treatment of
TKPT cells with cisplatin increased the binding of nu-
clear extracts to a consensus NF-jB binding sequence.
Treatment with salicylate prevented the cisplatin-induced
increase in NF-jB binding. The binding to the NF-jB se-
quence was specific as it was reduced by competition with
unlabeled NF-jB oligonucleotides, but not by competi-
tion with a mutant oligonucleotide. The promoter of the
TNF-a gene contains several NF-jB binding sites. It was
relevant, therefore, to determine the effects of cisplatin
and salicylate on TNF-a expression in TKPT cells. As
shown in Figure 10, cisplatin increased TNF-a mRNA in
TKPT cells 9-fold at 12 hours, while salicylate treatment
inhibited the cisplatin-induced TNF-a mRNA expression
significantly (P < 0.05) and also reduced basal TNF-a
expression.
Salicylate reduces cisplatin-induced apoptosis
in TKPT cells
The in vivo mechanisms of cisplatin nephrotoxicity
are complex and involve changes in renal hemodynamics
[22], inflammatory mechanisms [3–5], and direct cytotoxi-
city to renal epithelial cells [23–25]. In vitro, cisplatin can
result in either necrosis or apoptosis of renal epithelial
cells. We determined the effect of salicylate on cisplatin-
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Fig. 8. Effect of cisplatin and salicylate on the degradation of IjB in
renal proximal tubule cells. (Top). Mouse proximal tubule epithelial
(TKPT) cells were treated with control media, media containing 100
lmol/L cisplatin, or media containing cisplatin and 20 mmol/L sodium
salicylate for the indicated times. Cytosolic IjB was determined by
Western blot analysis. (Bottom). Densitometric analysis of IjB con-
tent of TKPT cells treated for 12 hours under the indicated conditions.
Data are summarized from three independent experiments. +P < 0.02
vs. control.
induced apoptosis in vitro, TKPT cells were treated with
100 lmol/L cisplatin for 12 hours in serum-free medium
with or without 20 mmol/L sodium salicylate. DNA frag-
mentation was determined as an indication of endonu-
clease activity associated with apoptosis. As reported by
Kaushal et al [26], cisplatin treatment increased DNA
fragmentation (Fig. 11). Salicylates effectively reduced
the extent of DNA fragmentation in the presence of cis-
platin (results representative of three experiments).
DISCUSSION
Cisplatin is an important antitumor agent used for
treating various solid tumors. The key limitation of this
drug is nephrotoxicity. Studies on the pathogenesis of cis-
platin nephrotoxicity have mainly focused on the direct
toxicity of cisplatin in vitro, including the role of oxidative
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Fig. 9. Effect of cisplatin and salicylate on nuclear factor kappa B (NF-
jB) binding activity in renal proximal tubule cells. Electromobility shift
assay was performed using nuclear extracts from mouse proximal tubule
epithelial (TKPT) cells were treated with control media, media contain-
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Fig. 10. Effect of cisplatin and salicylate on tumor necrosis factor a
(TNFa ) expression in renal proximal tubule cells. Mouse proximal
tubule epithelial (TKPT) cells were treated as in Fig. 8. for 12 hours.
TNF-a mRNA was determined by real time reverse transcription-
polymerase chain reaction (RT-PCR).
stress [25, 27, 28]. However, recent studies have demon-
strated the important role of inflammation and cytokine
activity in the pathogenesis of cisplatin nephrotoxicity [3–
5]. The recent observation that salicylate protects against
cisplatin nephrotoxicity [11] may also be relevant to the
role of inflammation. Salicylates are well known to re-
duce inflammation. However, the mechanism by which
salicylate protects against nephrotoxicity is not known.
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Fig. 11. Effect of cisplatin and salicylate on DNA fragmentation in
renal proximal tubule cells. Mouse proximal tubule epithelial (TKPT)
cells were treated under the indicated conditions for 12 hours. Cells
were harvested and low molecular DNA fragments were isolated as
described in Methods. Cisplatin increased DNA fragmentation. This
effect was inhibited by salicylate.
High doses of salicylate are thought to inhibit NF-jB and
its upstream activator IjB kinase b [9, 10], as opposed
to working through cyclooxygenase, the classic target of
nonsteroidal anti-inflammatory drugs. Activation of NF-
jB can increase the production of various inflammatory
cytokines, including TNF-a [21]. However, no data are
available regarding whether salicylate acts through inhi-
bition of TNF-a production. Therefore, the present study
addressed three major issues. First, having documented
an increase in TNF-a mRNA and protein in cisplatin in-
jury, to determine if salicylate treatment blunts the ac-
tivation of TNF-a systems within the kidney. Second,
to determine if the protective effects of salicylate are
referable to an inhibition of TNF-a production. Third, to
determine if salicylate prevents the degradation of IjB,
reduces NF-jB DNA binding activity and the increase in
TNF-a mRNA in vitro.
We confirmed the results of Li et al [11] by demonstrat-
ing a significant protective effect of salicylate on cisplatin
nephrotoxicity. In addition, we demonstrated preserva-
tion of renal histology and a reduction in necrosis, apop-
tosis, and renal leukocyte infiltration. As we, and others,
have reported [4, 5], kidney mRNA and protein levels for
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TNF-a were increased by cisplatin in vivo. In addition,
levels of TNFR1, TNFR2, MCP-1, ICAM-1, and HO-1
mRNA levels were increased. Treatment with salicylate
reduced the expression of TNF-a but not ICAM-1, MCP-
1, TNFR1, or HO-1. HO-1 is increased in response to ox-
idative stress as occurs in cisplatin injury [29]. Moreover,
increases in HO-1 protect the kidney against cisplatin in-
jury, while HO-1 knockout animals are more susceptible
to cisplatin injury [18]. Although salicylate has antioxi-
dant properties, the lack of any effect on HO-1 expression
suggests that this was not a major pathway for protection
against cisplatin injury. Likewise, the observation that
salicylate decreased leukocyte infiltration (Fig. 4), but
not ICAM-1 or MCP-1 expression, suggests that these
molecules are not sufficient to account for leukocyte in-
flux in cisplatin nephrotoxicity.
Salicylate decreased the expression of TNF-a and
TNFR2. In this regard, TNFR2 rather than TNFR1 is
the primary mediator of cisplatin nephrotoxicity [30].
We have shown, for instance, that cisplatin up-regulates
TNFR2 to a greater extent than TNFR1, and that the
up-regulation of TNFR2 by cisplatin is partly TNF-a–
dependent [30]. Moreover, TNFR2-deficient mice are re-
sistant to cisplatin nephrotoxicity. In this study, salicylate
caused only a modest, and not statistically significant, re-
duction in TNFR2. This may reflect the incomplete sup-
pression of TNF-a by salicylate, as opposed to the com-
plete absence of TNF-a in the TNF-a knockout mice used
in our previous study [30]. Finally, we demonstrated that
the protective effects of salicylate are markedly reduced
in the absence of TNF-a (Fig. 7). Accordingly, the results
of the present study indicate that inhibition of TNF-a pro-
duction is the major mechanism for the protective actions
of salicylate in cisplatin toxicity.
The sites of renal TNF-a production in cisplatin
nephrotoxicity are not certain. However, we found, like
Tsuruya et al [6], that cisplatin increases TNF-a mRNA
and protein in proximal tubule cells in vitro. Therefore,
we used this system to examine the effects of salicy-
late on TNF-a production. Salicylate decreased cisplatin-
induced TNF-a mRNA expression and inhibited both
cisplatin-induced IjB degradation and cisplatin-induced
NF-jB DNA binding activity. The latter findings are con-
sistent with the known ability of salicylate to inhibit the
activity of IKK [9]. Together, these observations suggest
that salicylates may reduce TNF-a transcription by sta-
bilizing IjB and preventing NF-jB from binding to the
TNF-a promoter [21].
Because salicylates and TNF-a antagonists reduce cis-
platin nephrotoxicity, it is relevant to consider their pos-
sible effects on the oncolytic actions of cisplatin. Li
et al [11] implanted tumors in mice and then administered
cisplatin alone or in conjunction with sodium salicylate.
No reduction in tumor killing was seen in the salicylate-
treated animals. Indeed, because NF-jB is a cell survival
factor [31], its inhibition by salicylate may increase the
effectiveness of chemotherapy. There are no compara-
ble data concerning the effects of TNF-a antagonism on
responses to chemotherapy. However, since salicylates
reduce TNF-a production (current study), but did not
reduce cisplatin anti-tumor efficacy [11], reduction of
TNF-a may not impact tumor killing. Likewise, because
TNF-a is a potent inducer of NF-jB activity, it is con-
ceivable that antagonism of TNF-a may sensitize tumors
to the effects of chemotherapy. Moreover, our observa-
tion that the nephrotoxicity of cisplatin is mediated via
TNFR2, while the anti-tumor actions of TNF-a are medi-
ated via TNFR1 [32], suggest that it should be possible to
devise strategies to inhibit nephrotoxicity without com-
promising the tumor-killing efficacy of cisplatin.
CONCLUSION
We have demonstrated both in vivo and in vitro that sal-
icylate attenuates cisplatin-induced TNF-a production,
leukocyte infiltration, and kidney dysfunction. The cur-
rent study, along with others [5, 6], indicates the impor-
tance of TNF-a pathways in cisplatin- induced acute renal
injury. Blockade of TNF-a production and/or action may
be effective in reducing cisplatin-induced acute renal in-
jury. However, further studies are needed to determine
the impact of TNF-a inhibition on the clinical efficacy of
cisplatin.
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